GlassScriptPhysician profile
Guillermo Amescua
NPI 1376734095
$54,456.83
in general payments reported to CMS, 2019-2025
23 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $1,189 · 2021: $6,156 · 2022: $8,238 · 2023: $6,053 · 2024: $8,637 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,525 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,200 · Food and Beverage: $2,606 · Travel and Lodging: $1,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,285.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,525.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,200.00 |
| Food and Beverage | $2,605.66 |
| Travel and Lodging | $1,037.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $31,010.37 | 2020-2025 | Product In Development |
| Bausch & Lomb Americas INC. | $8,105.86 | 2022-2025 | Envista Mx60 Iol, Envista Aspire Iol, Stellaris |
| Oyster Point Pharma, INC. | $4,537.49 | 2022-2025 | |
| Carl Zeiss Meditec, INC. | $4,400.00 | 2025 | Atlas 500, Callisto Eye, Visumax |
| Dompe Farmaceutici S.P.A. | $3,752.21 | 2025 | |
| Biotissue Holdings INC. | $423.07 | 2021-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $364.22 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $338.46 | 2025 | |
| Mallinckrodt Hospital Products INC. | $311.46 | 2022-2025 | Acthar |
| Alcon Vision LLC | $300.59 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $201.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $146.03 | 2021 | |
| Rxsight INC | $128.00 | 2022 | |
| Dompe US, INC. | $110.70 | 2024 | Oxervate |
| Carl Zeiss Meditec Cataract Technology INC. | $110.42 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $85.01 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $27.55 | 2025 | Xdemvy |
| Baudax Bio INC. | $23.08 | 2022 | |
| Harrow Eye, LLC | $22.79 | 2025 | Vevye |
| Santen INC. | $20.92 | 2023 | Verkazia |
| Mallinckrodt Enterprises LLC | $20.30 | 2019 | |
| Recordati_rare_diseases_inc. | $16.89 | 2023 | Cystadrops |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guillermo Amescua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.